Fred Hassan - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Director

Mr. Fred Hassan is Director of Amgen Inc. Mr. Fred Hassan was Partner and Managing Director at Warburg Pincus LLC, a global private equity investment institution, since 2011 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of ScheringPlough Corporationrationration from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of Pharmacia Corporationrationration, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of Pharmacia Corporationrationration from its creation in 2000 as a result of the merger of Pharmacia Upjohn, Inc. with Monsanto Company. He was President and Chief Executive Officer of Pharmacia Upjohn, Inc. beginning in 1997. Mr. Hassan previously held senior positions with Wyeth, including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at Sandoz Pharmaceuticals and headed its U.S. pharmaceuticals businesses.
Age: 70  Director Since 2015      
805-447-1000  http://www.amgen.com

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Carlos RepresasMerck Co
2009
Christopher CoughlinAllergan plc
2016
Karen VousdenBristol Myers Squibb Company
2018
Ronald TaylorAllergan plc
2013
Deborah NeffBio Rad Laboratories
2011
Paul RothmanMerck Co
2015
Jose BaselgaBristol Myers Squibb Company
2018
Michael GallagherAllergan plc
2015
Virgil ThompsonMallinckrodt Public Limited Com
2014
Michael EskewEli Lilly and Company
2008
David NortonMallinckrodt Public Limited Com
2017
Peter WendellMerck Co
2003
Juan LucianoEli Lilly and Company
2016
Arnold PinkstonBio Rad Laboratories
2017
Christopher BodineAllergan plc
2013
Dinesh PaliwalBristol Myers Squibb Company
2013
Paul CarterMallinckrodt Public Limited Com
2018
Catherine KlemaAllergan plc
2016
Angus RussellMallinckrodt Public Limited Com
2018
Alan GarberVertex Pharmaceuticals Incorpor
2017
Michael HyattEndo International plc
N/A

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Current Sentiment - AMGN

Amgen Investor Sentiment
Majority of Macroaxis users are presently bullish on Amgen. What is your sentiment towards investing in Amgen? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.